Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNC | P24863 | 17/20 | 1.00 |
| ▸ | CDK8 | P49336 | 17/20 | 1.00 |
| ▸ | CDK19 | Q9BWU1 | 2/20 | 0.71 |
| ▸ | TTK | P33981 | 3/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17437267 | 0.86 | CCNC (0.75) | CCNCCDK8CDK19TTK | |
| SCHEMBL20732974 | 0.86 | CCNC (0.75) | CCNCCDK8CDK19TTK | |
| SCHEMBL17437221 | 0.85 | CCNC (0.74) | CCNCCDK8CDK19TTK | |
| SCHEMBL17437036 | 0.85 | CCNC (0.76) | CCNCCDK8 | |
| SCHEMBL17437309 | 0.84 | CCNC (0.78) | CCNCCDK8CDK19 | |
| SCHEMBL17436947 | 0.83 | CCNC (1.00) | CCNCCDK8CDK19TTK | |
| SCHEMBL17437018 | 0.82 | CCNC (0.72) | CCNCCDK8 | |
| SCHEMBL17437093 | 0.82 | CCNC (1.00) | CCNCCDK8 | |
| SCHEMBL20732896 | 0.82 | CCNC (0.70) | CCNCCDK8CDK19TTK | |
| SCHEMBL17437220 | 0.82 | CCNC (1.00) | CCNCCDK8CDK19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3169678-A1 | NOVEL NAPHTHRYIDINES AND ISOQUINOLINES AND THEIR USE AS CDK8/19 INHIBITORS | Merck Patent GmbH (DE) | 2017-05-24 | — | — | EP | disclosed |
| US-20160016951-A1 | NOVEL NAPHTHYRIDINES AND ISOQUINOLINES AND THEIR USE AS CDK8/19 INHIBITORS | MERCK PATENT GMBH (DE) | 2016-01-21 | — | — | US | disclosed |
| US-20160016951-A1 | NOVEL NAPHTHYRIDINES AND ISOQUINOLINES AND THEIR USE AS CDK8/19 INHIBITORS | MERCK PATENT GMBH (DE) | 2016-01-21 | — | — | US | disclosed |
| US-20160016951-A1 | NOVEL NAPHTHYRIDINES AND ISOQUINOLINES AND THEIR USE AS CDK8/19 INHIBITORS | MERCK PATENT GMBH (DE) | 2016-01-21 | — | — | US | disclosed |
| WO-2016009076-A1 | NOVEL NAPHTHRYIDINES AND ISOQUINOLINES AND THEIR USE AS CDK8/19 INHIBITORS | MERCK PATENT GMBH (DE) | 2016-01-21 | — | — | WO | disclosed |
| WO-2016009076-A1 | NOVEL NAPHTHRYIDINES AND ISOQUINOLINES AND THEIR USE AS CDK8/19 INHIBITORS | MERCK PATENT GMBH (DE) | 2016-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160016951-A1 | NOVEL NAPHTHYRIDINES AND ISOQUINOLINES AND THEIR USE AS CDK8/19 INHIBITORS | CDK8, CDK9, CDK18 | CCNC 31/4885CDK8 1/4885CDK19 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.